Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MS
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
MS has been associated with fatigue, attention problems, and a number of cognitive
difficulties. There is no treatment approved yet to treat these problems. We hypothesize that
the addition of Provigil to an existing immunomodulatory agent (Avonex) will lead to improved
fatigue, attention, and overall cognition in MS patients with attention problems.